Man ‘Likely Cured’ of HIV After Stem Cell Donation from Brother Who Has Rare Blood Mutation

A 63-year-old man known as the “Oslo patient” appears to have been cured of HIV following a stem cell transplant, according to a recent study published in the journal Nature. This remarkable case provides hope for individuals living with the virus, although it also highlights the need for broader strategies to combat the global HIV epidemic.

The Oslo patient, who was initially diagnosed with HIV in 2006 at the age of 44, had managed his condition with effective antiretroviral therapies until 2017. It was then that he noticed troubling symptoms such as fatigue and a decrease in blood cell levels, which eventually led to a diagnosis of myelodysplastic syndromes—a type of cancer affecting the bone marrow.

Following unsuccessful attempts at conventional treatments for his cancer, medical professionals sought a suitable bone marrow donor. They specifically looked for a donor with a rare genetic mutation known as CCR5 delta 32, which has been shown in prior studies to provide significant protection against HIV infections. Unfortunately, a suitable donor could not be found. However, the patient’s 60-year-old brother proved to be a match to assist with the treatment for the bone marrow cancer.

In an unexpected twist, it was discovered on the day of the transplant in November 2020 that the brother possessed two copies of the CCR5Δ32 mutation, enhancing the chances of the procedure’s success. Dr Marius Trøseid, a professor and infectious disease specialist at Oslo University Hospital, commented on the fortuitous nature of the situation, stating that the patient effectively “won the lottery twice”—he was cured not only of his cancer but also of HIV.

Four years following the transplant, analysis showed no detectable HIV in the patient’s blood or gut biopsies. The study reported that there was an absence of any intact HIV DNA, suggesting that the patient is likely cured of the virus. Furthermore, tests indicated “full donor chimerism” in the gut, which is significant since this area is known to serve as the primary reservoir for the virus in HIV-infected individuals. This means that the patient’s blood cells are entirely derived from his brother, lending further credibility to the assertion of a cure.

Despite this landmark case, experts assert that the approach of using stem cell transplants is not feasible for the majority of people living with HIV. Dr Trøseid emphasised that although the case of the Oslo patient is encouraging, it underlines the necessity for innovative strategies in the fight against HIV—especially considering that more than 30 million individuals worldwide are currently living with the virus.

The Oslo patient’s story presents a turning point in understanding the possibilities for curing HIV. While it shines a light on the advancements healthcare has made in this area, it also poses important questions about accessibility to such life-changing treatments. As researchers continue to explore alternative methods to combat HIV, this case provides both hope and a reminder of the complexity surrounding the search for a universal cure.

With on-going investments and studies aimed at developing broadly applicable treatments, the medical community remains optimistic about future breakthroughs in HIV management and the potential to enhance the quality of life for millions affected by this virus.